BNB Plus Corp. (BNBX)
BNB Plus Corp. operates in the Biotechnology industry of the Healthcare sector, headquartered in Stony Brook, NY, US. The stock last traded at $0.16, up 0.00% on the session, giving a market capitalisation of $210,492. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -1646.9%. Its beta of 0.55 implies it has historically moved less than the broad market.
BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production. The MDx Testing Services segment concentrates on developing clinical molecular diagnostic and genetic assessments, in addition to providing comprehensive clinical laboratory testing services. Lastly, the DNA Tagging and Security Products and Services segment leverages DNA detection techniques for securing industrial supply chains and offering various security solutions.
BNB Plus Corp. is most often compared with the following Healthcare names: